Cargando…
Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report
Keratoacanthoma (KA) is a benign epidermal tumor, characterized by rapid and abundant growth, a tendency toward spontaneous regression and histopathologic similarity to squamous cell carcinoma (SCC). Because KA can be easily misdiagnosed as SCC, surgery is considered the treatment of choice. Recentl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162267/ https://www.ncbi.nlm.nih.gov/pubmed/21909208 http://dx.doi.org/10.5021/ad.2011.23.3.357 |
_version_ | 1782210801804771328 |
---|---|
author | Jeon, Hye Chan Choi, Mira Paik, Seung Hwan Ahn, Chang Ho Park, Hyun Sun Cho, Kwang Hyun |
author_facet | Jeon, Hye Chan Choi, Mira Paik, Seung Hwan Ahn, Chang Ho Park, Hyun Sun Cho, Kwang Hyun |
author_sort | Jeon, Hye Chan |
collection | PubMed |
description | Keratoacanthoma (KA) is a benign epidermal tumor, characterized by rapid and abundant growth, a tendency toward spontaneous regression and histopathologic similarity to squamous cell carcinoma (SCC). Because KA can be easily misdiagnosed as SCC, surgery is considered the treatment of choice. Recently, regression of KAs following application of 5% imiquimod cream (Aldara®) has been reported. We present 4 cases of KA treated with topical imiquimod, applied 3 to 4 times a week. Obvious improvement was observed after 4 to 6 weeks of application and the lesions were almost cleared leaving scars after 9 to 11 weeks. These results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported. We also suggest that lesions treated with imiquimod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment. |
format | Online Article Text |
id | pubmed-3162267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Korean Dermatological Association; The Korean Society for Investigative Dermatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-31622672011-09-09 Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report Jeon, Hye Chan Choi, Mira Paik, Seung Hwan Ahn, Chang Ho Park, Hyun Sun Cho, Kwang Hyun Ann Dermatol Case Report Keratoacanthoma (KA) is a benign epidermal tumor, characterized by rapid and abundant growth, a tendency toward spontaneous regression and histopathologic similarity to squamous cell carcinoma (SCC). Because KA can be easily misdiagnosed as SCC, surgery is considered the treatment of choice. Recently, regression of KAs following application of 5% imiquimod cream (Aldara®) has been reported. We present 4 cases of KA treated with topical imiquimod, applied 3 to 4 times a week. Obvious improvement was observed after 4 to 6 weeks of application and the lesions were almost cleared leaving scars after 9 to 11 weeks. These results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported. We also suggest that lesions treated with imiquimod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment. Korean Dermatological Association; The Korean Society for Investigative Dermatology 2011-08 2011-08-06 /pmc/articles/PMC3162267/ /pubmed/21909208 http://dx.doi.org/10.5021/ad.2011.23.3.357 Text en Copyright © 2011 Korean Dermatological Association; The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Jeon, Hye Chan Choi, Mira Paik, Seung Hwan Ahn, Chang Ho Park, Hyun Sun Cho, Kwang Hyun Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report |
title | Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report |
title_full | Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report |
title_fullStr | Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report |
title_full_unstemmed | Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report |
title_short | Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report |
title_sort | treatment of keratoacanthoma with 5% imiquimod cream and review of the previous report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162267/ https://www.ncbi.nlm.nih.gov/pubmed/21909208 http://dx.doi.org/10.5021/ad.2011.23.3.357 |
work_keys_str_mv | AT jeonhyechan treatmentofkeratoacanthomawith5imiquimodcreamandreviewofthepreviousreport AT choimira treatmentofkeratoacanthomawith5imiquimodcreamandreviewofthepreviousreport AT paikseunghwan treatmentofkeratoacanthomawith5imiquimodcreamandreviewofthepreviousreport AT ahnchangho treatmentofkeratoacanthomawith5imiquimodcreamandreviewofthepreviousreport AT parkhyunsun treatmentofkeratoacanthomawith5imiquimodcreamandreviewofthepreviousreport AT chokwanghyun treatmentofkeratoacanthomawith5imiquimodcreamandreviewofthepreviousreport |